PDS Biotech to Showcase PDS0301 Data in Colorectal Cancer KOL Event…

Event summary

PDS Biotech will host a virtual KOL event on October 15, 2026, featuring Dr. Jonathan M. Hernandez to discuss Phase 2 trial outcomes for PDS0301 in advanced colorectal cancer with liver metastases.
PDS0301 is an investigational IL-12 immunocytokine designed to target and deliver IL-12 into tumors to promote immune cell infiltration and anti-tumor activation.
The event will focus on the treatment of second and third-line unresectable microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal liver metastases.
PDS0301 has been clinically evaluated across multiple solid tumors, including metastatic colorectal cancer and prostate cancer.

The big picture

PDS Biotech's KOL event highlights the strategic focus on advancing PDS0301 for a challenging patient population where immunotherapy has historically been ineffective. The event underscores the company's efforts to position its lead asset in a competitive oncology market, with broader implications for the adoption of targeted immunotherapies in solid tumors. The outcomes discussed could influence future clinical strategies and partnership opportunities.

What we're watching

Clinical Efficacy: How the Phase 2 trial outcomes for PDS0301 will impact its development and potential approval in advanced colorectal cancer.
Market Positioning: Whether PDS Biotech can differentiate PDS0301 in a competitive immunotherapy landscape, particularly for MSS/pMMR colorectal cancer.
Strategic Partnerships: The pace at which PDS Biotech secures partnerships or external funding for the Phase 3 development of PDS0101.